Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France.
| Revenue (Most Recent Fiscal Year) | $13.12M |
| Net Income (Most Recent Fiscal Year) | $-10.09M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -69.03% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.00 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 18.28M |
| Free Float | -- |
| Market Capitalization | $215.70M |
| Average Volume (Last 20 Days) | 0.00 |
| Beta (Past 60 Months) | -0.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |